Anzeige
Meldung des Tages: Revolutionäre Entwicklung im Megatrend – Der KI-Durchbruch für Pflege und Sicherheit!

Hoth Therapeutics Aktie News

Aktie
WKN:  A3DZJ0 ISIN:  US44148G2049 US-Symbol:  HOTH Branche:  Biotechnologie Land:  USA
0,7852 $
-0,0534 $
-6,37%
0,6655 € 19:04:47 Uhr
Depot/Watchlist
Marktkapitalisierung *
11,28 Mio. €
Streubesitz
87,82%
KGV
-1,23
Index-Zuordnung
-

Hoth Therapeutics News

18.06.25 - PR Newswire
Hoth Therapeutics Regains Nasdaq Compliance - Clears Key Listing Hurdle, Reaffirms Path Toward Growth
Hoth Therapeutics Regains Nasdaq Compliance - Clears Key Listing Hurdle, Reaffirms Path Toward Growth PR Newswire
18.06.25 - PR Newswire
Hoth Therapeutics Reports Positive Preclinical Safety Data for Cancer Fighting HT-KIT -- Dose-Dependent Liver Activity with No Observed Toxicity Supports IND Pathway
Hoth Therapeutics Reports Positive Preclinical Safety Data for Cancer Fighting HT-KIT -- Dose-​Dependent Liver Activity with No Observed Toxicity Supports IND Pathway PR Newswire
16.06.25 - PR Newswire
Hoth Therapeutics to Attend 2025 BIO International Convention
Hoth Therapeutics to Attend 2025 BIO International Convention PR Newswire
12.06.25 - PR Newswire
Hoth Therapeutics Secures Japanese Patent for Breakthrough HT-KIT Platform Targeting Mast Cell Diseases
Hoth Therapeutics Secures Japanese Patent for Breakthrough HT-KIT Platform Targeting Mast Cell Diseases PR Newswire
11.06.25 - PR Newswire
Hoth Therapeutics Launches Expanded Access Initiative for HT-001, Offering Critical Relief to Cancer Patients Facing Severe Skin Toxicities
Hoth Therapeutics Launches Expanded Access Initiative for HT-001, Offering Critical Relief to Cancer Patients Facing Severe Skin Toxicities PR Newswire
05.06.25 - PR Newswire
Hoth Therapeutics to Spotlight HT-001 in Investor-Focused KOL Event Addressing Breakthrough Combating Cancer Treatment Skin Toxicities
Hoth Therapeutics to Spotlight HT-001 in Investor-​Focused KOL Event Addressing Breakthrough Combating Cancer Treatment Skin Toxicities PR Newswire
12.05.25 - PR Newswire
/C O R R E C T I O N -- Hoth Therapeutics, Inc./
/C O R R E C T I O N -- Hoth Therapeutics, Inc./ PR Newswire
17.04.25 - PR Newswire
Hoth Therapeutics Announces Granted Japanese Patent for Novel RNA-Based Cancer Therapy Targeting KIT Gene - Expands Global IP in Precision Oncology Platform
Hoth Therapeutics Announces Granted Japanese Patent for Novel RNA-Based Cancer Therapy Targeting KIT Gene - Expands Global IP in Precision Oncology Platform PR Newswire
15.04.25 - PR Newswire
Hoth Therapeutics Announces Positive Initial Data in Phase 2a Clinical Trial
Hoth Therapeutics Announces Positive Initial Data in Phase 2a Clinical Trial PR Newswire
02.04.25 - PR Newswire
Hoth Therapeutics Collaborates with Washington University on NIH Grant Application Advancing Alzheimer's Program Using NK-1 Receptor Antagonist HT-ALZ
Hoth Therapeutics Collaborates with Washington University on NIH Grant Application Advancing Alzheimer's Program Using NK-1 Receptor Antagonist HT-ALZ PR Newswire
31.03.25 - PR Newswire
Hoth Therapeutics Receives USPTO Filing Receipt for HT-001 Formulation Patent Application, Expanding Existing Patent Coverage
Hoth Therapeutics Receives USPTO Filing Receipt for HT-001 Formulation Patent Application, Expanding Existing Patent Coverage PR Newswire
26.03.25 - PR Newswire
Hoth Therapeutics Advances Cancer Fighting HT-KIT Program with New Patent Filing and Preclinical Study Initiation
Hoth Therapeutics Advances Cancer Fighting HT-KIT Program with New Patent Filing and Preclinical Study Initiation PR Newswire
18.03.25 - PR Newswire
Hoth Therapeutics Announces Positive Preclinical Results for HT-KIT in Aggressive Cancer Gastrointestinal Stromal Tumors (GIST). HT-KIT Triggered Significant Tumor Cell Death as Early as 24 Hours Post-treatment
Hoth Therapeutics Announces Positive Preclinical Results for HT-KIT in Aggressive Cancer Gastrointestinal Stromal Tumors (GIST). HT-KIT Triggered Significant Tumor Cell Death ...
10.03.25 - PR Newswire
Hoth Therapeutics Announces Plans to Submit Expanded Access Application for HT-001 to Support Cancer Patients in Need
Hoth Therapeutics Announces Plans to Submit Expanded Access Application for HT-001 to Support Cancer Patients in Need PR Newswire
05.03.25 - PR Newswire
Hoth Therapeutics Announces Positive Results for HT-001 in Treating EGFR Inhibitor-Associated Papulopustular Eruptions Findings to be Presented at the American Academy of Dermatology 2025 Annual Meeting
Hoth Therapeutics Announces Positive Results for HT-001 in Treating EGFR Inhibitor-​Associated Papulopustular Eruptions Findings to be Presented at the American Academy of ...
04.03.25 - PR Newswire
Hoth Therapeutics Announces Positive Findings on GDNF's Potential as a Game-Changer in Obesity Treatment and Reduced Fatty Liver Disease
Hoth Therapeutics Announces Positive Findings on GDNF's Potential as a Game-​Changer in Obesity Treatment and Reduced Fatty Liver Disease PR Newswire
10.02.25 - PR Newswire
Hoth Therapeutics Partners with OnTargetx R&D to Advance Research for Cancer fighting HT-KIT Cancer Therapeutic
Hoth Therapeutics Partners with OnTargetx R&D to Advance Research for Cancer fighting HT-KIT Cancer Therapeutic PR Newswire

Newssuche

Videos

newspaper
03.02.26
2026 02 03 17 34 Trendjumper Einführung
Zunächst inormieren wir unsere Stammkunden bezüglich des bevorstehenden Seminars und bieten für ... Mehr »